Mural Oncology data for IL-18 and IL-12 programs presented at AACR

Mural Oncology shared poster presentations with pre-clinical data from its Interleukin-18, IL-18 and IL-12 programs at the American Association for Cancer Research AAC annual meeting taking place April 5-10 in San Diego, California. This is the first time Mural has shared findings from either program. The details for the presentations are as follows, and both posters are available at https://www.muraloncology.com/publications/. Interleukin-18 engineered for resistance to IL-18 binding protein, IL-18BP, and half-life extension to enhance its therapeutic potential…IL-18 is a potent immune-stimulating cytokine, but it is limited by IL-18 binding protein – a secreted high affinity decoy receptor that binds with, and neutralizes, IL-18, thus limiting its efficacy over time. Mural’s protein engineering approach is twofold: first, it introduces mutations to IL-18 that are designed to minimally impact the structure while eliminating binding to IL-18BP. Secondly, it fuses IL-18 to protein scaffolds to extend the half-life and increase the cytokine’s exposure. The company believes the half-life enhancement may lead to a more durable immunological effect, as demonstrated by the interferon gamma and Th1 response, proinflammatory reactions necessary for the body’s immune response.